Payment overview · 2025
General Payments
$34,127.66
109 reported records · 20 companies
Healthcare provider profile · identity verified
Matthew Varacallo, MD
Allopathic & Osteopathic Physicians|Orthopaedic Surgery|Sports Medicine · DU BOIS, PA · NPI 1629415682
Verified facts
What the public records show
CMS Open Payments records show Matthew Varacallo, MD received $34,127.66 in general payments during 2025 across 109 reported records.
Smith+Nephew, Inc. accounted for 55.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 52 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $18,990.62 | 55.6% | 31 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $4,638.69 | 13.6% | 5 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $4,048.48 | 11.9% | 12 | 2025 |
| Medical Device Business Services, Inc. | Unresolved — no canonical attribution shown | $1,781.17 | 5.2% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $1,618.26 | 4.7% | 19 | 2025 |
| Arthrex, Inc. | Unresolved — no canonical attribution shown | $1,238.53 | 3.6% | 10 | 2025 |
| Mid-Atlantic Surgical Systems, LLC | Unresolved — no canonical attribution shown | $1,177.91 | 3.5% | 10 | 2025 |
| Coastal Medical Technologies LLC | Unresolved — no canonical attribution shown | $197.85 | 0.6% | 2 | 2025 |
| Curonix LLC | Unresolved — no canonical attribution shown | $72.50 | 0.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $60.88 | 0.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.08 | 0.1% | 2 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.47 | 0.1% | 2 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $41.50 | 0.1% | 2 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $37.15 | 0.1% | 1 | 2025 |
| Medline Industries LP | Unresolved — no canonical attribution shown | $25.93 | 0.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$25.40 | 0.1% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $23.93 | 0.1% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $20.57 | 0.1% | 1 | 2025 |
| HERAEUS MEDICAL, LLC. | Unresolved — no canonical attribution shown | $18.98 | 0.1% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $18.76 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $14,670.00 | 7 |
| Travel and Lodging | $8,173.76 | 18 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,800.00 | 1 |
| Food and Beverage | $3,451.63 | 82 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $8,466.21 | 5 | 2025 |
Source payment records
|
|||||
| STRAVIX MESH Normalized: stravix mesh |
Biological | Smith+Nephew, Inc. | $7,800.00 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX PL Normalized: stravix pl |
Biological | Smith+Nephew, Inc. | $7,800.00 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $6,477.93 | 4 | 2025 |
Source payment records
|
|||||
| GRAFIX Normalized: grafix |
Biological | Smith+Nephew, Inc. | $6,450.00 | 2 | 2025 |
Source payment records
|
|||||
| GRAFIX XC Normalized: grafix xc |
Biological | Smith+Nephew, Inc. | $6,450.00 | 2 | 2025 |
Source payment records
|
|||||
| NA Normalized: na |
Device | Smith+Nephew, Inc. | $5,850.00 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC, Medical Device Business Services, Inc. | $5,781.34 | 11 | 2025 |
Source payment records
|
|||||
| Exparel Normalized: exparel |
Drug | Pacira Pharmaceuticals Incorporated | $4,590.30 | 3 | 2025 |
Source payment records
|
|||||
| EVARREST Normalized: evarrest |
Biological | Ethicon US, LLC | $2,790.00 | 3 | 2025 |
Source payment records
|
|||||
| SURGICEL NU-KNIT Normalized: surgicel nu knit |
Device | Ethicon US, LLC | $2,790.00 | 3 | 2025 |
Source payment records
|
|||||
| SURGIFLO Hemostatic Matrix Normalized: surgiflo hemostatic matrix |
Device | Ethicon US, LLC | $2,790.00 | 3 | 2025 |
Source payment records
|
|||||
| ACUFEX Meniscal Root Repair Normalized: acufex meniscal root repair |
Device | Smith+Nephew, Inc. | $2,730.03 | 5 | 2025 |
Source payment records
|
|||||
| CAP-FIX Normalized: cap fix |
Device | Smith+Nephew, Inc. | $1,735.75 | 4 | 2025 |
Source payment records
|
|||||
| HEALICOIL Normalized: healicoil |
Device | Smith+Nephew, Inc. | $1,735.75 | 4 | 2025 |
Source payment records
|
|||||
| NovoStitch Normalized: novostitch |
Device | Smith+Nephew, Inc. | $1,735.75 | 4 | 2025 |
Source payment records
|
|||||
| Q-FIX Normalized: q fix |
Device | Smith+Nephew, Inc. | $1,735.75 | 4 | 2025 |
Source payment records
|
|||||
| SYSTEM 9 CD NXT Normalized: system 9 cd nxt |
Device | Stryker Corporation | $1,365.20 | 11 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $1,029.96 | 4 | 2025 |
Source payment records
|
|||||
| DERMABOND PRINEO Normalized: dermabond prineo |
Device | Ethicon US, LLC | $930.00 | 1 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $930.00 | 1 | 2025 |
Source payment records
|
|||||
| OASIS Normalized: oasis |
Device | Smith+Nephew, Inc. | $803.39 | 2 | 2025 |
Source payment records
|
|||||
| BIOBRANE Normalized: biobrane |
Device | Smith+Nephew, Inc. | $600.00 | 1 | 2025 |
Source payment records
|
|||||
| Bioinductive Implant with Arthroscopic Delivery System - Medium Normalized: bioinductive implant with arthroscopic delivery system medium |
Device | Smith+Nephew, Inc. | $145.20 | 1 | 2025 |
Source payment records
|
|||||
| Iovera Normalized: iovera |
Device | Pacira Pharmaceuticals Incorporated | $96.17 | 2 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $94.14 | 7 | 2025 |
Source payment records
|
|||||
| PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A Normalized: pns freedom 4a permanent neurostimulator receiver kit channel a |
Device | Curonix LLC | $72.50 | 1 | 2025 |
Source payment records
|
|||||
| MAKO Normalized: mako |
Device | Stryker Corporation | $72.25 | 4 | 2025 |
Source payment records
|
|||||
| INSPACE Normalized: inspace |
Device | Stryker Corporation | $67.79 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $60.88 | 3 | 2025 |
Source payment records
|
|||||
| Zilretta Normalized: zilretta |
Drug | Pacira Pharmaceuticals Incorporated | $48.39 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.08 | 2 | 2025 |
Source payment records
|
|||||
| Bone Anchors with Arthroscopic Delivery System Normalized: bone anchors with arthroscopic delivery system |
Device | Smith+Nephew, Inc. | $46.49 | 2 | 2025 |
Source payment records
|
|||||
| CALDOLOR Normalized: caldolor |
Drug | Cumberland Pharmaceuticals, Inc. | $43.47 | 2 | 2025 |
Source payment records
|
|||||
| MONOVISC Normalized: monovisc |
Device | DePuy Synthes Sales Inc. | $41.50 | 2 | 2025 |
Source payment records
|
|||||
| ORTHOVISC Normalized: orthovisc |
Device | DePuy Synthes Sales Inc. | $41.50 | 2 | 2025 |
Source payment records
|
|||||
| Channel Drain Normalized: channel drain |
Device | Becton, Dickinson and Company | $37.15 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $34.00 | 1 | 2025 |
Source payment records
|
|||||
| MicroAire Normalized: microaire |
Device | Smith+Nephew, Inc. | $28.63 | 1 | 2025 |
Source payment records
|
|||||
| SPATIAL FRAME Normalized: spatial frame |
Device | Smith+Nephew, Inc. | $28.63 | 1 | 2025 |
Source payment records
|
|||||
| DERMABOND Normalized: dermabond |
Device | Ethicon US, LLC | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| 3M Cavilon Normalized: 3m cavilon |
Device | Solventum Corporation | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| PALACOS Normalized: palacos |
Device | HERAEUS MEDICAL, LLC. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| TRIATHLON Normalized: triathlon |
Device | Stryker Corporation | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| MONOCRYL Normalized: monocryl |
Device | Ethicon US, LLC | $14.30 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34,127.66 · 109 records | Smith+Nephew, Inc. | 3M Cavilon, ACTIV.A.C., ACUFEX Meniscal Root Repair, BIOBRANE, Bioinductive Implant with Arthroscopic Delivery System - Medium, Bone Anchors with Arthroscopic Delivery System, CALDOLOR, CAP-FIX, CLOTTRIEVER BOLD CATHETER, Channel Drain, DERMABOND, DERMABOND PRINEO, ETHICON, EVARREST, Exparel, GRAFIX, GRAFIX PL, GRAFIX XC, HEALICOIL, INCEPTIV, INSPACE, Iovera, JOURNAVX, MAKO, MONOCRYL, MONOVISC, MicroAire, NA, NovoStitch, OASIS, ORTHOVISC, PALACOS, PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A, Q-FIX, RENASYS TOUCH, Restrata Wound Matrix, SIMPONI, SIMPONI ARIA, SPATIAL FRAME, STELARA, STRATAFIX, STRAVIX, STRAVIX MESH, STRAVIX PL, SURGICEL NU-KNIT, SURGIFLO Hemostatic Matrix, SYSTEM 9 CD NXT, TREMFYA, TRIATHLON, VISTASEAL, Wegovy, Zilretta | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error